Department of Hematology, West China Hospital, Sichuan University, Chengdu, 610041, China.
J Hematol Oncol. 2020 Dec 7;13(1):167. doi: 10.1186/s13045-020-00996-x.
Despite considerable progress has been achieved in the treatment of acute myeloid leukemia over the past decades, relapse remains a major problem. Novel therapeutic options aimed at attaining minimal residual disease-negative complete remission are expected to reduce the incidence of relapse and prolong survival. Natural killer cell-based immunotherapy is put forward as an option to tackle the unmet clinical needs. There have been an increasing number of therapeutic dimensions ranging from adoptive NK cell transfer, chimeric antigen receptor-modified NK cells, antibodies, cytokines to immunomodulatory drugs. In this review, we will summarize different forms of NK cell-based immunotherapy for AML based on preclinical investigations and clinical trials.
尽管在过去几十年中，急性髓细胞白血病的治疗已经取得了相当大的进展，但复发仍然是一个主要问题。旨在实现微小残留病阴性完全缓解的新治疗选择有望降低复发率并延长生存期。自然杀伤细胞为基础的免疫疗法被提出作为解决未满足的临床需求的一种选择。已经有越来越多的治疗方法，包括过继性 NK 细胞转移、嵌合抗原受体修饰的 NK 细胞、抗体、细胞因子和免疫调节剂。在这篇综述中，我们将根据临床前研究和临床试验总结基于 NK 细胞的免疫疗法在 AML 中的不同形式。
